Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. Based in Langhorne, Pennsylvania, the company's lead product candidate is molgramostim (MOLBREEVI), an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Molgramostim is currently in Phase 3 clinical development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition characterized by the buildup of surfactant in the alveoli. The company is preparing for regulatory submissions in the United States and Europe, aiming to provide the first approved pharmacologic treatment for aPAP. Savara operates primarily in the United States and utilizes a proprietary investigational eFlow Nebulizer System for the delivery of its inhaled biologic.
